Introduction
Influenza remains a significant threat to global public health, and causes high morbidity and mortality in immunocompromised, elderly, and paediatric populations (Costantino and Vitale, 2016) . While vaccination is the most common method for preventing influenza, the protection it provides heavily depends on the antigenic match between the vaccine strains and the circulating viruses, and the age and health status of the recipient (Lambert and Fauci, 2010) . Antiviral drugs provide another option for the control of influenza, and can be used either as short-term prophylaxis to prevent infection, or as a therapeutic to reduce viral replication and duration of illness post-infection (Byrn et al., 2015) . Antivirals play a particularly important role in the treatment of severely ill patients with influenza, and in the event of a pandemic when pre-existing immunity is lacking and an appropriately matched vaccine is unavailable (Naesens et al., 2016) . Two classes of licensed influenza antiviral drugs are currently available, the adamantanes (M2 ion channel blockers), and the neuraminidase inhibitors (NAIs). However, the adamantanes are no longer recommended for influenza treatment because currently circulating influenza A viruses are resistant to this class of antivirals (Hurt, 2014) .
The two NAIs licensed in many countries, oseltamivir (the most widely used NAI) and zanamivir, can reduce the duration of uncomplicated influenza illness when administered within 48 h of symptom onset (Dobson et al., 2015) . In addition, treatment with oseltamivir has been shown to reduce rates of hospitalisation and mortality, (Fiore et al., 2011; Louie et al., 2012) . Although the frequency of resistance to the NAIs is low in currently circulating influenza viruses (approximately 0.5%) (Hurt et al., 2016) , the emergence and rapid spread of oseltamivir-resistance in seasonal H1N1 viruses in [2007] [2008] highlighted the limitations of this class of antiviral drug, and is cause for concern should another NAI resistant strain become prevalent. Furthermore, the therapeutic use of antivirals remains problematic when treating immunocompromised patients who typically have prolonged virus shedding (Fiore et al., 2011) , due to the increased likelihood of resistance developing during extended courses of antiviral treatment . There is a need for new influenza antivirals that are less likely to select for resistance and that are more effective in treating influenza patients from high risk groups, particularly when treatment is delayed by more than 48 h after symptom onset. Development of influenza antivirals has accelerated in the last decade, and several novel compounds that exert anti-influenza activity by targeting either viral or host proteins are currently in various stages of development (Koszalka et al., 2017) . Among them is the thiazolide compound nitazoxanide (NTZ).
NTZ was originally developed as an anti-protozoal drug, and is currently licensed for the treatment of Cryptosporidium and Giardia infections (Rossignol et al., 2009) . In addition to anti-parasitic activity, NTZ, via its active metabolite tizoxanide (TIZ), also exhibits antibacterial activity against a range of anaerobic bacteria, as well as broad spectrum in vitro antiviral activity against influenza, respiratory syncytial virus, norovirus, rotavirus, and hepatitis B and C viruses (Rossignol, 2014) .
The broad spectrum antiviral activity of NTZ can be attributed to the fact that it targets host cell mechanisms rather than the virus, although the specific mode of action differs depending on the virus (Rossignol, 2014) . In the case of influenza, NTZ inhibits the function of the endoplasmic reticulum (ER) protein ERp57, which is essential for the maturation of the influenza virus hemagglutinin (HA), and posttranslational trafficking from the ER to the Golgi (Rossignol, 2017) .
In vitro NTZ susceptibility has previously been determined for a panel of eight reference influenza A viruses representing H1N1, H3N2, H5N9, H7N1 subtypes, with reported IC 50 values of 1.0-3.2 μM across the panel (Belardo et al., 2015) . NTZ also inhibited the growth of two variant H3N2 influenza viruses with mean IC 90 values of 1.09 μM and 0.86 μM (Sleeman et al., 2014) . Rossignol et al. (2009) , reported equivalent antiviral activity for both NTZ and TIZ, and TIZ EC 50 values of 0.3-0.5 μg/mL (1.1-1.9 μM) for the three reference viruses, A/PR/8/ 34 (H1N1), A/WSN/33 (H1N1) and A/Ck/It/9097/97 (H5N9). Furthermore NTZ and TIZ also exhibited equal potency against three isolates of canine influenza virus with EC 50 values of 0.2 μM reported for both compounds (Ashton et al., 2010) . These results are not surprising given that NTZ is readily hydrolysed to TIZ in aqueous buffers such as cell culture medium (Broekhuysen et al., 2000) .
NTZ has been effective in treating patients with uncomplicated influenza in a Phase IIb/III trial (Haffizulla et al., 2014) . A placebo controlled Phase III trial is currently underway to investigate treatment with NTZ versus oseltamivir versus NTZ plus oseltamivir combination in patients with uncomplicated influenza (ClinicalTrials.gov: NCT01610245).
Although in vitro NTZ/TIZ susceptibility has been identified for a small number of influenza reference viruses, data are not available for a large number of seasonal influenza viruses. Here we describe the TIZ susceptibility of 210 recently circulating seasonal influenza viruses, including NAI-resistant viruses. This provides baseline TIZ susceptibility data for A(H1N1)pdm09, A(H3N2), and B influenza viruses. In addition, we describe in detail the development of a focus reduction assay that is well suited to determining the TIZ susceptibility of a large number of surveillance isolates.
Materials and methods

Antiviral compounds
TIZ was supplied by Romark Laboratories, (Tampa, Florida, USA). 50 mM stocks were prepared in dimethyl sulfoxide (DMSO; Sigma, USA), sterilised using 0.2 μm surfactant-free cellulose acetate (SFCA) filters (ThermoFisher, USA), and aliquots stored at −20°C. Working solutions of TIZ were prepared from frozen stocks by further dilution in DMSO, followed by a final dilution in cell culture media immediately prior to assay setup.
Cells and viruses
Madin-Darby canine kidney (MDCK) cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured in MDCK cell growth medium (MGM) [Dulbecco's modified Eagles medium (DMEM; Gibco, USA) supplemented with 10% foetal bovine serum (FBS; Bovogen Biologicals, AUS), 100U/mL PenicillinStreptomycin, 20 μM HEPES, 0.06% Sodium Bicarbonate, 1x MEM nonessential amino acids (NEAA), and 1x GlutaMAX, (Gibco, USA)]. MDCK-SIAT cells (MDCK cells modified to overexpress α 2,6-linked sialic acids) were kindly provided by Dr. M. Matrosovich (Matrosovich et al., 2003) and maintained in MDCK-SIAT cell growth medium (SGM) [MGM supplemented with 1 mg/mL Geneticin (Gibco, USA)]. All cell maintenance and cell-based in vitro assays were carried out in humidified incubators with 5% CO 2 .
Influenza viruses 
Cytotoxicity assays
The cytotoxicity of TIZ was determined in MDCK and MDCK-SIAT cells to identify a suitable non-toxic concentration range for use in the susceptibility assay. MDCK cells (3.5 × 10 4 cells/well, 100 μl/well), and MDCK-SIAT cells (2.5 × 10 4 cells/well, 100 μl/well), were seeded into flat-bottom 96-well plates (Corning, USA) in MGM and SGM respectively, and incubated overnight at 37°C. Confluent cell monolayers were washed with phosphate buffered saline (PBS; Sigma, USA), and 100 μl of a 2-fold serial dilution of TIZ (0.4-100 μM) in MM was added to cells. The final DMSO concentration in each well was 0.5%. Due to the low solubility of TIZ in aqueous solutions, concentrations greater than 100 μM were not tested. DMSO at 0.5% in MM was added to cell only control wells. Cytotoxicity was assessed using the CellTiterGlo cell viability assay (CTG; Promega, USA), and the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; MP Biomedicals, USA) assay, following incubation of plates for 24 h at 35°C. The CTG assay was performed as per manufacturer's instructions, and luminescence was measured using a FLUOstar Optima luminometer (BMG Labtech, Germany). The procedure for the MTT assay was based on previously described methods (Mosmann, 1983) . Briefly, cell monolayers were incubated for 4 h in the presence of 1 mg/mL MTT at 37°C. The supernatant was removed and 200 μl isopropanol (Sigma, USA) added to dissolve the purple formazan that was produced. Absorbance was measured at 570 nm using a Multiskan Ascent plate reader (Thermo Fisher, USA). The 50% cytotoxic concentration for TIZ (CC 50 ; drug concentration that reduced the cell viability by 50% compared to the cell only control) was determined using nonlinear regression analysis (GraphPad Prism, USA) for both cytotoxicity readouts.
Titration of virus
To determine the appropriate viral input for the focus reduction assay, a virus titration was performed for each virus. MDCK and MDCK-SIAT cells were seeded in 96-well plates overnight as previously described (Section 2.3). Half-log dilutions of each virus were prepared in MM in a 96 well U-bottom plate. Cell monolayers were washed with PBS and 50 μl of each virus dilution was added to the plates, followed by incubation at 35°C for 90 min. Mock-infected cells in MM served as a cell-only control. After incubation, the virus/mock inoculum was removed. Monolayers were then washed with PBS to remove unbound virus and overlaid with 100 μl infection medium [IM; equal parts 3.2% carboxymethyl cellulose (CMC; Sigma Aldrich, USA) and 2x DMEM [Sigma Aldrich (USA), containing 20 μM HEPES (Gibco, USA), 100 U/ mL Penicillin-Streptomycin (Gibco, USA), 0.06% Sodium Bicarbonate (Gibco, USA), and 1 μg/mL L-tosylamido 2-phenylethyl chloromethyl ketone (TPCK)-treated trypsin (Worthington, USA)] and 0.5% DMSO. Plates were then incubated at 35°C for either 8, 16, 24 or 30 h, after which IM was removed, and cells were fixed and immunostained using methods described previously (van Baalen et al., 2017) with some minor modifications. Briefly, the IM was removed and the cells were fixed for 15 min at room temperature (RT) with 100 μl 10% formalin (Sigma Aldrich, USA). After removing the fixative and washing the cell monolayers with 150 μl PBS, then 100 μl 0.5% Triton X-100 (Sigma Aldrich, USA) in PBS was added to all wells and the plates were incubated for 10 min at RT. The plates were then washed three times with 0.05% Tween 20 (Sigma Aldrich, USA) in PBS, and the cells were incubated for 1 h with a mouse anti-influenza monoclonal antibody against influenza A virus nucleoprotein (Millipore, USA, Cat#MAB8251) or against influenza B virus nucleoprotein (Millipore, USA, Cat#MAB8661), diluted 1:5000 in blocking solution (2% skim milk powder in PBS). After repeating the washing step, cells were incubated for 1 h with goat anti-mouse HRP-conjugated secondary antibody (BioRad, USA) diluted 1:1000 in blocking solution. The washing step was repeated, and the infected cells were stained with 50 μl True Blue peroxidase substrate (KPL, USA) for 10 min in the dark. The plates were washed with Milli-Q water three times and allowed to dry completely. Plate images were captured and the number of focus forming units (FFU) per well quantified using an Immunospot analyser and Biospot software (CTL Immunospot, USA). The parameters used for counting FFU were set up to reflect one focus unit to represent one individual virus infected cell (Table S1 Supplementary material). Virus dilutions that resulted in approximately 1000 FFU/well were used in subsequent focus reduction assays.
Focus reduction assay
The susceptibility of influenza viruses to TIZ was determined by measuring the reduction in FFU in the presence of the drug. Confluent monolayers of MDCK or MDCK-SIAT cells in 96 well plates (seeded overnight as described previously), were washed with PBS and 50 μl of virus diluted to approximately 1000 FFU/well as determined previously, was added to each well of the culture plates. 50 μL of MM was added to cell control wells. After incubation for 90 min at 35°C the virus/mock inoculum was removed. Cell monolayers were washed once with PBS, and overlaid with 2-fold serial dilutions of TIZ (0.08-10 μM) in 100 μL IM. IM +0.5% DMSO was added to virus control and cell control wells, and the plates were incubated at 35°C for 8, 16, 24 or 30 h. Plates were then immunostained as described in Section 2.4, and the number of foci/well determined as described above. Each virus was tested against each TIZ concentration in duplicate wells and a mean number of FFU calculated for each pair. Using the mean FFU, the percentage inhibition of FFU was calculated by formula 100-[(X-CC)/(VC-CC) x100], where X = FFU in test wells (virus + drug at each concentration), CC= FFU in cell control wells (no virus, to account for background), and VC=FFU in virus control wells (no drug).
The 50% effective concentration of TIZ for each virus (EC 50 ; drug concentration that inhibited FFU formation by 50% compared to the cell only control) was determined using non-linear regression analysis (GraphPad Prism, USA).
Statistical methods
Linear regression analysis, unpaired student's t-tests, and Kruskall Wallis tests were performed using GraphPad Prism (USA) (P < 0.05 was considered statistically significant). Statistical plots were constructed using R version 3.1.2 (R Foundation for Statistical Computing, Austria). To evaluate assay reproducibility, focus reduction assays were performed with replicate (N = 48) wells of positive and negative controls ( ± virus) on a 96-well plate and Z factors were calculated using the equation outlined in Zhang et al. (1999) .
Results
Cytotoxicity of TIZ
To determine the maximum non-toxic concentration for use in the susceptibility assay, the effect of TIZ on the viability of MDCK and MDCK-SIAT cells was determined using the CellTiterGlo assay and MTT assay over a 24 h incubation period. In both cell lines the CC 50 of TIZ was higher in the MTT assay readout compared to the CellTiterGlo assay (Table 1 ). The CC 50 of TIZ was > 100 μM and 61.2 ± 15.1 μM in the MTT assay in MDCK and MDCK-SIAT cells respectively, compared to 77.1 ± 17.9 μM and 47.8 ± 18.9 μM for MDCK and MDCK-SIAT cells using CellTiterGlo. To avoid underestimating cytotoxicity of TIZ, the results from the CellTiterGlo cytotoxicity assays were used to select a maximum test concentration of 10 μM for use in all further experiments. At this concentration and below, the viability of both cell lines was ≥80%.
Determination of optimal assay conditions
The appearance of foci, reproducibility, and EC 50 values for TIZ were examined at 8, 16, 24, and 30 h post infection (hpi) in both MDCK and MDCK-SIAT cells, using six representative viruses [2x A(H1N1) pdm09, 2x A(H3N2), 2x influenza B viruses]. Foci produced at 8 hpi for all subtypes were low in intensity and fewer in number in comparison to other time points (Fig. 1) . In addition, 2-fold variations in foci number were observed in duplicate wells for some viruses at 8 hpi, therefore this time point was not analysed further. Examination of Z factors for all time points indicated that the assay was more reproducible (i.e. Z factors were closer to 1) when outside wells were omitted from the analysis (Fig. 2A) . Therefore only Z factors calculated in the absence of the outside wells were used to select assay duration. A Z factor of > 0.5 is considered a requirement for an assay to deliver reproducible and accurate results. Z-factors > 0.5 were observed at 16 and 24 h for A(H1N1)pdm09 viruses and A(H3N2) viruses, and 16, 24, and 30 h for influenza B viruses using both cell lines. For influenza A viruses, EC 50 values dropped markedly from 16 to 24 h, suggesting that a 24 h assay duration is required to achieve a complete antiviral effect (Fig. 2B) . For influenza B viruses, the EC 50 values were similar at 16 h, 24 h, and 30 h (Fig. 2B) . For all subtypes/types, comparable Z factors were obtained in each cell line, and while marginally lower EC 50 values were obtained in MDCK-SIAT cells compared to MDCK cells, either cell line is considered suitable for performing the susceptibility assay. Taking into account these findings, and the convenience of choosing a single protocol that was suitable for testing all types/subtypes, all further virus titrations and susceptibility assays were carried out using a duration of 24 h with MDCK-SIAT cells. In order to assess inter-assay variability, the same six representative viruses were tested for TIZ susceptibility in an additional 3-6 assays using these optimised conditions, and the mean EC 50 and standard deviation was calculated for each virus (Table S2 supplementary material). Due to the small standard deviations of the mean EC 50 for each virus, the inter-assay variability was considered minimal and therefore allowed testing of each test virus in a single assay. The viral inoculum is an important parameter, and had to be high enough to produce a statistically significant number of foci, yet not too great to compromise drug sensitivity. As a result of initial titration experiments, the virus dilution that yielded approximately 1000 foci per well was used as the virus input. A plot of the number of foci versus virus dilution produced a sigmoidal curve, and for all viruses, 1000 foci fell in the lower linear region indicative of suitable sensitivity. However, we investigated the significance of small variations in virus input and the subsequent impact on the final EC 50 result. The range of FFU in the virus control well that resulted in comparable and accurate TIZ EC 50 values was tested for four representative viruses from different subtypes/lineages. Comparable EC 50 values were obtained for each virus when the FFU/well was in the range of 200-2500 (Fig. S2 supplementary material) . Therefore, while 1000 foci/well was the target virus input, the assay was considered valid if the FFU/well of the virus control was in the range of 200-2500.
TIZ susceptibility of circulating seasonal influenza viruses
The in vitro TIZ susceptibility of 210 seasonal influenza viruses (54x A(H1N1)pdm09, 53x A(H3N2), 56x B/Yamagata lineage and 47x B/ Victoria lineage) circulating from the period March 2014 to August 2016, was assessed in a 24 h assay in MDCK-SIAT cells. TIZ showed potent activity against all influenza viruses tested (Fig. 3) , with median EC 50 values of 0.48 μM, 0.62 μM, 0.66 μM, and 0.60 μM for A(H1N1) pdm09, A(H3N2), B(Victoria lineage), and B(Yamagata lineage) influenza viruses respectively. There was no significant difference between the median values for each subtype (P > 0.05), although a larger range of EC 50 values was observed for the influenza A virus subtypes [0.1-1.23 μM for A(H1N1)pdm09 viruses and 0.22-1.14 μM for A(H3N2 influenza viruses] than for both B lineage viruses (0.34-0.88 μM and 0.25-0.92 μM for B/Victoria lineage and B/Yamagata lineage viruses respectively).
TIZ susceptibility of neuraminidase inhibitor-resistant influenza viruses
A panel of fourteen circulating influenza viruses with reduced susceptibility to NAIs was also assessed for susceptibility to TIZ. All NAIresistant viruses tested were susceptible to TIZ (Table 2) , and furthermore there was no significant difference between mean TIZ EC 50 of NAI-sensitive viruses and NAI-resistant viruses, 0.61 μM and 0.62 μM respectively (P > 0.05).
Discussion
Ongoing surveillance of the antiviral susceptibility of circulating viruses to currently available influenza antivirals, the adamantanes and NAIs, has been important for the detection of emerging resistant viruses, identification of the genetic mutations that confer resistance, and ultimately for guiding therapeutic options for patients requiring treatment (Hurt et al., 2016; Kossyvakis et al., 2017; Takashita et al., 2015) . With the potential licensure of several new influenza therapeutics, including nitazoxanide, cell-based susceptibility assays that are amenable to screening a large number of viruses are required for surveillance purposes. Traditionally, cell-based yield reduction assays have been used extensively for the assessment of influenza antivirals, including nitazoxanide (Ashton et al., 2010; Belardo et al., 2015; Byrn et al., 2015; Jones et al., 2016; Perwitasari et al., 2014; Sleeman et al., 2014) . However this assay format is very laborious and time consuming, and is therefore unsuitable for screening a large number of samples. Focus reduction assays have recently become a useful method for the antigenic characterisation of influenza viruses, particularly A(H3N2) viruses that have lost the ability to agglutinate red blood cells (Lin et al., 2015; Terletskaia-Ladwig et al., 2013; van Baalen et al., 2017) . Here, we have utilised the virus infectivity detection method recently developed for antigenic characterisation assays (van Baalen et al., 2017) , to assess the TIZ susceptibility of recently circulating seasonal influenza viruses and NAI-resistant viruses. The assay method enabled rapid and direct determination of the reduction of virus infectivity in the presence of TIZ, and was amenable to the analysis of a large number of viruses. TIZ was selected for use in the assay, rather than NTZ, as it is the active metabolite form, however the use of NTZ in this assay generated highly similar results (data not shown). As is typical with surveillance testing of circulating viruses for NAI susceptibility (Takashita et al., 2015) , each virus was tested in a single assay with repeat confirmatory testing necessary if the EC 50 value was outside the typical range. In addition, this assay format could be utilised for the determination of the susceptibility of influenza viruses to other antiviral drugs.
The potent activity of TIZ against 210 circulating A(H1N1)pdm09, A(H3N2), B (Victoria lineage), and B (Yamagata lineage) influenza viruses shown in the present study, was similar to previous in vitro data which report EC 50 values for laboratory reference viruses of these subtypes/types ranging from 1.1 μM to 5.6 μM (0.3-1.5 μg/mL) (Rossignol, 2014) . In contrast to the reduced oseltamivir-susceptibility of circulating influenza B viruses compared to influenza A viruses (Farrukee et al., 2015) , there was no significant difference in the median TIZ EC 50 values for influenza A and influenza B viruses. However, there was a greater range of EC 50 values for influenza A virus subtypes than for influenza B viruses, although the reason for this is currently unknown.
Historically, the majority of FDA-approved drugs used to treat human virus infections have targeted viral enzymes (de Chassey et al., 2014) . While a number of compounds that directly target specific influenza viral proteins are currently in pre-clinical and clinical development, several host targeted compounds are also being investigated (Koszalka et al., 2017) . These compounds, such as nitazoxanide, act on host cellular functions that are essential for virus replication. Because the emergence of viruses resistant to host cell targeted antivirals is less likely compared to virus targeted compounds (Loregian et al., 2014) , drugs acting on host cellular functions will be of particular importance for treatment of viruses such as influenza which have a high rate of mutation.
While preliminary reports indicate that the likelihood of selecting TIZ resistant virus is low (Belardo et al., 2011) , further studies to investigate the propensity of influenza viruses developing resistance to TIZ in vitro, in vivo, and in clinical settings will be important. The methods described here provide a means for the surveillance of influenza virus susceptibility to TIZ, and furthermore may be used to test other influenza antiviral drugs under development that require cell based assays.
